None listed
Conditions
Brief summary
Endoscopic sinus surgery (ESS) is recognised to be an effective treatment for chronic rhinosinusitis but the ideal post-operative care after ESS is not defined. Tranexamic acid (TXA) is a cheap, readily available medication that stabilises blood clot formation. There are limited data regarding the use of intraoperative topical TXA in ESS with promising results but no studies in the published literature regarding post-operative outcomes. The study hypothesis is that direct application of TXA after ESS improves outcomes and patient recovery.
Interventions
Intervention: application of 5ml of tranexamic acid (500mg / 5ml) topically to the sinus and nasal mucosa for 60 minutes after endoscopic sinus surgery via cotton pledgets
No issue with adherence as patients anaesthetised / emerging from anaesthesia.
Sponsors
The University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult patient undergoing comprehensive bilateral endoscopic sinus surgery for the treatment of idiopathic chronic rhinosinusitis as defined by the EPOS 2012 guidelines
Exclusion criteria
Use of tranexamic acid contraindicated owing to history of clotting disorder or thromboembolic disease. Condition which is know to predispose to chronic rhinosinusitis (e.g. cystic fibrosis, vasculitis, primary ciliary dyskinesia)
Outcome results
None listed